openPR Logo
Press release

U.S. Contraceptives Drugs And Devices Market, By Product Type (Contraceptive Drugs, Contraceptive Devices (Male Contraceptive Devices, Female Contraceptive Devices)) - Insights, Opportunity Analysis, and Industry Forecast till 2024

05-29-2017 02:38 PM CET | Advertising, Media Consulting, Marketing Research

Press release from: Coherent Market Insights

U.S. Contraceptives Drugs And Devices Market, By Product Type

Contraceptive Drugs and Devices – Choice to Conceive, Not Concede

As per stats released by Guttmacher Institute, there were around 61 million women in the U.S. in the childbearing age group (15-44 years) in 2014. Around 10% of these women do not use any contraceptive method. The UN estimates (2015) that unmet need for contraceptives in the North America region is 7%. Thus, there still is an untapped market in the U.S. that contraceptive manufacturers can address. Furthermore, with no-cost coverage insurance policy for sterilization, growth for U.S. contraceptive drugs and devices market is restricted.

Statistics revealed by the United Nations in 2015, mentions that sterilization is a dominant contraceptive method in regions such as North America. Intra-uterine devices (IUDs), vaginal rings, injectables, implants, combined oral contraceptives, and patches are some of the advanced contraceptive methods available in the market. Therefore, various strategies such as promotion through sales force, social media promotion, awareness campaigns, and sampling are adopted by companies marketing contraceptive drugs and devices in the U.S. Introduction of new male contraceptive products with high success rate are projected to shape the course of growth of the U.S. contraceptive drugs and devices market in the near future.

Request Sample Copy of Research @ https://www.coherentmarketinsights.com/insight/request-sample/368

The global U.S. contraceptive drugs and devices market was valued at US$ 6,785.9 million in 2016 and is expected to expand at a CAGR of 5.6% during the forecast period (2016 – 2024)

Oral pills resulting in volatility in the U.S. contraceptive drugs and devices market

Private companies have high interest in selling contraceptive pills as they generate continuous revenues for them compared to one-time long acting contraceptive methods. Furthermore, patent expiration is projected to lead to a barrage of generics entering into the market, further reducing overall average cost of drugs and in turn market revenue. Global generic pharmaceutical companies such as Teva Pharmaceuticals, Lupin Laboratories and Cipla Limited are at pace to launch their generic versions. Emergency contraceptive pills are among the most popular category of pills owing to extensive promotion activities to market these products.

Favorable reimbursement scenario pushing uptake of contraceptives among low and middle-income population

The U.S. Affordable Care Act emphasizes on complete insurance coverage for long-acting reversible contraceptives (LARC). However, market players are interested in sustainable revenue generating oral pills. This public-private interest disparity impacts cost and product availability in different sections of the society.

Furthermore, the State announced insurance coverage of health and reproductive products to continue without any co-pays, co-insurance or deductibles. In addition to this, the new policy would also cover all medically essential abortion services for the U.S. population. This is a much anticipated relief for the general population in the U.S., where around 45% of all pregnancies reported are unintended (CDC, 2009-2013 study data).

Ask For Request Discount: https://www.coherentmarketinsights.com/insight/request-discount/368

Insurance coverage for devices also varies from state to state in the U.S. Few states have low Medicaid reimbursement rates than the cost of the device, while few states provide reimbursement only to those women who have been prescribed such devices. For instance, in California, dispensing of injectable contraceptives is only allowed by clinics, while Alabama, Idaho, and South California do not cover emergency contraceptive pills as part of the Medicaid programs in their respective states. Many such limitations in Medicaid coverage creates disparity in demand for certain contraceptives across regions in the U.S. Efforts to standardize the rule all over the country is expected to benefit the population at large and the overall U.S. contraceptive drugs and devices market.

Preference for modern contraceptive methods

Higher success rate and availability of reimbursement is encouraging women to opt for these methods over contraceptive pills. With increasing consumer awareness and rising accessibility to modern contraceptives methods, demand for these products is expected to increase during the forecast period. As per the United Nation’s 2015 report, 9 out of 10 married or in-union women opt for modern contraceptive methods. Furthermore, gynecologists and sexologists are recommending use of long-acting reversible contraceptives for couples who do not intend to have a child in near future, owing to their high affectivity compared to conventional contraceptives such as oral hormonal pills.

Browse Market Research Report @ https://www.coherentmarketinsights.com/ongoing-insight/us-contraceptives-drugs-and-devices-market-368

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release U.S. Contraceptives Drugs And Devices Market, By Product Type (Contraceptive Drugs, Contraceptive Devices (Male Contraceptive Devices, Female Contraceptive Devices)) - Insights, Opportunity Analysis, and Industry Forecast till 2024 here

News-ID: 551520 • Views: 291

More Releases from Coherent Market Insights

Medical Holography Market - Detailed Analysis of Current and Future Industry Fig …
Global Medical Holography Market Insights, Forecast to 2027 is latest research study re-leased by CMI evaluating the market, highlighting opportunities, risk side analysis, and lever-aged with strategic and tactical decision-making support. The study provides information on market trends and development, drivers, capacities, technologies, and on the changing investment structure of the Global Medical Holography Market. Some of the key players profiled in the study are HoloTech Switzerland AG, RealView Imaging
Video Telemedicine Market - Detailed Analysis of Current and Future Industry Fig …
Global Video Telemedicine Market Insights, Forecast to 2027 is latest research study re-leased by CMI evaluating the market, highlighting opportunities, risk side analysis, and lever-aged with strategic and tactical decision-making support. The study provides information on market trends and development, drivers, capacities, technologies, and on the changing investment structure of the Global Video Telemedicine Market. Some of the key players profiled in the study are Huawei technologies Co.  Ltd., Polycom
Clinical Data Management Market - Detailed Analysis of Current and Future Indust …
Global Clinical Data Management Market Insights, Forecast to 2027 is latest research study re-leased by CMI evaluating the market, highlighting opportunities, risk side analysis, and lever-aged with strategic and tactical decision-making support. The study provides information on market trends and development, drivers, capacities, technologies, and on the changing investment structure of the Global Clinical Data Management Market. Some of the key players profiled in the study are OmniComm Systems, Oracle
Computer Aided Detection Market - Detailed Analysis of Current and Future Indust …
Global Computer Aided Detection Market Insights, Forecast to 2027 is latest research study re-leased by CMI evaluating the market, highlighting opportunities, risk side analysis, and lever-aged with strategic and tactical decision-making support. The study provides information on market trends and development, drivers, capacities, technologies, and on the changing investment structure of the Global Computer Aided Detection Market. Some of the key players profiled in the study are GE Healthcare, Philips

All 5 Releases


More Releases for Contraceptive

Contraceptive Pills
Oral contraceptive pills is a kind of female hormonal anti-conception medication technique that is used for avoiding pregnancy. Contraceptive drugs are used to prevent the unwanted pregnancy by blocking the normal process of ovulations or by altering the process which support the fertilization of egg. The prevalence of women with unmet contraception needs was accounted at 214 million in 2018 by WHO. Further, as indicated by, United Nations,
Intrauterine Contraceptive Devices Market Future Opportunities 2025
Intrauterine contraceptive device (IUD) is a T-shaped, small-sized, birth control device that is inserted into woman’s uterus to prevent pregnancy. These devices are highly effective, economical, and safe birth control devices. IUDs are considered 99% safe in preventing pregnancy. The contraceptive effect of IUDs is attributable to the localized inflammation that occurs after insertion. The inflammatory reaction in the uterus produces substances that are poisonous for sperms. This affects fertilization.
Asia-Pacific Contraceptive Drugs Market Report 2017
The Values marked with XX is confidential data. To know more about CAGR figures fill in your information so that our business development executive can get in touch with you. In this report, the Asia-Pacific Contraceptive Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Request Sample Copy
Oral Contraceptive Pills Market: Regional & Competitive Analysis
According to TMR, the global oral contraceptive pills market is expected to be worth US$22.9 bn by 2023. On the basis of type, the position of combination oral contraceptive pill segment remains undisputed and is estimated to be worth US$18 bn by 2023. The segment is also identified as the fastest growing segment within the market. On the basis of category, the generic oral contraceptive pill segment will lead in
Intrauterine Contraceptive Devices (IUD) Market | Size | Analysis
Intrauterine devices (IUDs) are contraceptive medical implants used to avoid pregnancies for a long time period. IUD’S are also known as long-acting reversible contraceptive devices. An IUD is a T-shaped device which is made of flexible plastic along with a copper wire wrapped around its stem and is a reliable and safe method of sterilization for women. It is injected into the uterus, and their primary aim is to inhibit
Oral Contraceptive Pills Market: Snapshot
Teva Pharmaceutical is one of the leading companies in the combination oral contraceptive pills segment and is followed by Allergan (Actavis) plc. Local manufacturers such as Alkem, Taj Pharma, and Zydus Alidec on the other hand, held a majority of the market for ormeloxifene and mifepristone. Transparency Market Research has observed that almost all manufacturers offer combination oral contraceptive pills owing to the fact that they are more efficient, cost